Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 33.66
+9.86 (41.43%)
Aug 20, 2026, 4:09 PM HKT
Everest Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,408 | 1,707 | 706.68 | 125.93 | 12.79 | 0.05 | |
Revenue Growth | 182.91% | 141.51% | 461.16% | 884.46% | 23588.89% | - |
Cost of Revenue | 726.62 | 524.82 | 181.8 | 34.41 | 4.65 | 0.02 |
Gross Profit | 1,682 | 1,182 | 524.88 | 91.52 | 8.15 | 0.03 |
Selling, General & Admin | 1,238 | 1,057 | 758.15 | 396.57 | 603.23 | 440.83 |
Research & Development | 571.88 | 511.04 | 528.04 | 540.05 | 809.74 | 613.43 |
Other Operating Expenses | -13.85 | -42.35 | 18.91 | 6.16 | -0.12 | -4.96 |
Operating Expenses | 1,796 | 1,526 | 1,305 | 942.78 | 1,413 | 1,049 |
Operating Income | -113.94 | -343.89 | -780.21 | -851.27 | -1,405 | -1,049 |
Interest Expense | -23.27 | -23.27 | -22.19 | -23.06 | -5.59 | -4.81 |
Interest & Investment Income | 116.01 | 116.01 | 95.21 | 107.67 | 38.48 | 28.88 |
Earnings From Equity Investments | -79.08 | -39.15 | - | - | - | - |
Currency Exchange Gain (Loss) | 9.11 | 9.11 | 19.51 | -28.07 | -155.18 | 22.94 |
Other Non Operating Income (Expenses) | 21.32 | 26.2 | 2.65 | 2.82 | -1.61 | -6.46 |
EBT Excluding Unusual Items | -69.86 | -255 | -685.03 | -791.91 | -1,529 | -1,009 |
Gain (Loss) on Sale of Investments | 75.57 | -13.47 | -0.01 | 0.85 | -21.75 | - |
Gain (Loss) on Sale of Assets | -0.03 | -0.03 | - | -1.43 | 1,320 | - |
Asset Writedown | -333.23 | -333.23 | -356.34 | -51.97 | -16.49 | - |
Other Unusual Items | 3.37 | 3.37 | - | - | - | - |
Pretax Income | -324.18 | -598.36 | -1,041 | -844.46 | -247.28 | -1,009 |
Income Tax Expense | -270.26 | -300.6 | - | - | 0.01 | - |
Net Income | -53.92 | -297.77 | -1,041 | -844.46 | -247.28 | -1,009 |
Net Income to Common | -53.92 | -297.77 | -1,041 | -844.46 | -247.28 | -1,009 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 323 | 336 | 321 | 313 | 298 | 293 |
Shares Outstanding (Diluted) | 323 | 336 | 321 | 313 | 298 | 293 |
Shares Change | 0.03% | 4.84% | 2.51% | 5.18% | 1.49% | 243.61% |
EPS (Basic) | -0.17 | -0.89 | -3.24 | -2.70 | -0.83 | -3.44 |
EPS (Diluted) | -0.17 | -0.89 | -3.24 | -2.70 | -0.83 | -3.44 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -281.69 | -156.57 | -744.92 | -886.53 | -1,512 | -839.89 |
Free Cash Flow Per Share | -0.87 | -0.47 | -2.32 | -2.83 | -5.08 | -2.86 |
Gross Margin | 69.83% | 69.25% | 74.27% | 72.67% | 63.69% | 57.41% |
Operating Margin | -4.73% | -20.15% | -110.41% | -675.97% | -10981.12% | -1943096.30% |
Profit Margin | -2.24% | -17.45% | -147.36% | -670.57% | -1933.11% | -1867998.15% |
Free Cash Flow Margin | -11.70% | -9.17% | -105.41% | -703.97% | -11817.36% | -1555344.44% |
EBITDA | 24.62 | -211.18 | -670.04 | -795.72 | -1,391 | -1,043 |
EBITDA Margin | 1.02% | -12.37% | -94.82% | - | - | - |
D&A For EBITDA | 138.56 | 132.71 | 110.17 | 55.55 | 13.81 | 6.21 |
EBIT | -113.94 | -343.89 | -780.21 | -851.27 | -1,405 | -1,049 |
EBIT Margin | -4.73% | -20.15% | -110.41% | - | - | - |